Business Context and Reporting Period
This Form 8-K is a current report filed by Millendo Therapeutics, Inc. (MLND) on June 13, 2019. The filing addresses the departure of a senior executive and the subsequent public announcement of this event.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on corporate governance and personnel changes rather than financial performance.
Material Changes
- Executive Departure: Dr. Pharis Mohideen notified the Company on June 13, 2019, of his resignation as Chief Medical Officer.
- Effective Date: The resignation is effective July 12, 2019.
- Reason for Departure: Dr. Mohideen is resigning to pursue a career closer to his home in New Jersey to spend more time with his family.
- Public Disclosure: A press release announcing the departure was issued on June 18, 2019.
Guidance, Outlook, and Risks
The filing does not contain updated financial guidance, management commentary on future outlook, or specific risk factors beyond the operational impact of the executive departure. No unusual items or contingencies were disclosed in this report.
Investor Verification Checklist
- Verify the appointment of an interim or permanent replacement for the Chief Medical Officer role.
- Review the full text of the press release (Exhibit 99.1) for additional context on the transition plan.
- Confirm whether the departure impacts the Company's ongoing clinical trials or drug development timelines.